<DOC>
	<DOC>NCT00646178</DOC>
	<brief_summary>Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severely Active Psoriatic Arthritis Subjects with Inadequate Response to Disease Modifying anti-Rheumatic Drug Therapy</brief_summary>
	<brief_title>Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate to severe PsA Inadequate response to DMARD therapy Corticosteroid stable dose &lt;=10 mg QD DMARDs must have been taken for 3 months and stable dose for 4 weeks MTX maximum dose = &lt;=30 mg/week Active chronic plaque PS or documented history of chronic plaque PS No other active skin disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>